Protein Z-dependent protease inhibitor (ZPI) is a physiologically significant inhibitor of prothrombinase function

• Published in: The Journal of biological chemistry 2019-05, Vol.294 (19), p.7644-7657
• Main Authors: Huang, Xin, Swanson, Richard, Kroh, Heather K., Bock, Paul E.
• Format: Article
• Language: English
• Subjects: Amino Acid Substitution; Antibodies - chemistry; Blood Coagulation; coagulation factor; Enzymology; Factor V - chemistry; Factor V - genetics; Factor V - metabolism; factor Va; factor Xa; Factor Xa - chemistry; Factor Xa - genetics; Factor Xa - metabolism; Humans; Kinetics; Mutation, Missense; protease; protease inhibitor; Protein C - chemistry; Protein C - metabolism; protein Z; protein Z-dependent protease inhibitor; prothrombin; Prothrombin - chemistry; Prothrombin - genetics; Prothrombin - metabolism; prothrombinase; serpin; Serpins - chemistry; Serpins - genetics; Serpins - metabolism; Thrombin - chemistry; Thrombin - genetics; Thrombin - metabolism
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.RA118.006787

Current thought holds that factor Xa (FXa) bound in the prothrombinase complex is resistant to regulation by protein protease inhibitors during prothrombin activation. Here we provide evidence that, contrary to this view, the FXa-specific serpin inhibitor, protein Z-dependent protease inhibitor (ZPI), complexed with its cofactor, protein Z (PZ), functions as a physiologically significant inhibitor of prothrombinase-bound FXa during prothrombin activation. Kinetics studies showed that the rapid rate of inhibition of FXa by the ZPI-PZ complex on procoagulant membrane vesicles (ka(app) ∼107m−1 s−1) was decreased ∼10-fold when FXa was bound to FVa in prothrombinase and a further ∼3–4–fold when plasma levels of S195A prothrombin were present (ka(app) 2 × 105m−1 s−1). Nevertheless, the ZPI-PZ complex produced a major inhibition of thrombin generation during prothrombinase-catalyzed activation of prothrombin under physiologically relevant conditions. The importance of ZPI-PZ complex anticoagulant regulation of FXa both before and after incorporation into prothrombinase was supported by thrombin generation assays in plasma. These showed enhanced thrombin generation when the inhibitor was neutralized with a PZ-specific antibody and decreased thrombin generation when exogenous ZPI-PZ complex was added whether prothrombin was activated directly by FXa or through extrinsic or intrinsic pathway activators. Moreover, the PZ antibody enhanced thrombin generation both in the absence and presence of activated protein C (APC) anticoagulant activity. Taken together, these results suggest an important anticoagulant role for the ZPI-PZ complex in regulating both free FXa generated in the initiation phase of coagulation as well as prothrombinase-bound FXa in the propagation phase that complement prothrombinase regulation by APC.